Disease-modifying treatment does not influence severity and recovery of the first relapse after treatment onset in RRMS: insights from four large-scale clinical trials

Background: Relapses are the defining clinical feature of relapsing-remitting multiple sclerosis, but it remains uncertain whether disease-modifying treatments influence relapse severity or recovery once a relapse occurs. We investigated whether disease-modifying treatment exposure affects the severity of and recovery from clinical relapses across four pivotal phase 3 relapsing-remitting multiple sclerosis trials. Methods: We used logistic regression models to assess predictors of severe first relapse (Expanded Disability Status Scale worsening > 1.0 point), and Cox proportional hazards models to evaluate factors associated with time to recovery. Predictors included age, sex, disease duration, baseline Expanded Disability Status Scale, T2 lesion volume, contrast-enhancing lesions, relapse severity, corticosteroid treatment and treatment arm. Results: Across all trials, disease-modifying treatments significantly reduced the annualized relapse rate (p < 0.0001) compared to placebo or interferon as an active comparator, but were not associated with relapse severity or recovery time. Relapse recovery followed a similar two-phase course in all trials, with most recovery occurring within 90–120 days. Treatment arm and corticosteroid use were not significantly associated with the time to recovery in any dataset. Conclusions: While disease-modifying treatments reduce relapse frequency, they did not modify relapse severity or recovery once a relapse occurred. These findings suggest that disease-modifying treatments primarily prevent inflammatory events rather than alter their clinical evolution.

Authors

Institutions

Publication Details

Journal
Multiple Sclerosis Journal
Published
2026-11-19
DOI
https://doi.org/10.1177/13524585261502632
Primary Topic
Multiple Sclerosis Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Disease-modifying treatment does not influence severity and recovery of the first relapse after treatment onset in RRMS: insights from four large-scale clinical trials

Jop P. Mostert, Marcus Werner Koch, Pavle Repovic, Øivind Torkildsen et al.
Multiple Sclerosis Journal
Multiple Sclerosis Research Studies
article

Disease-modifying treatment does not influence severity and recovery of the first relapse after treatment onset in RRMS: insights from four large-scale clinical trials

Jop P. Mostert, Marcus Werner Koch, Pavle Repovic, Øivind Torkildsen, Eva M. M. Strijbis, Tarrant McPherson, Gary Cutter, Miguel D’haeseleer, Jacynthe Comtois, Ester Moral, Luis Brieva
article en

Abstract

Background: Relapses are the defining clinical feature of relapsing-remitting multiple sclerosis, but it remains uncertain whether disease-modifying treatments influence relapse severity or recovery once a relapse occurs. We investigated whether disease-modifying treatment exposure affects the severity of and recovery from clinical relapses across four pivotal phase 3 relapsing-remitting multiple sclerosis trials. Methods: We used logistic regression models to assess predictors of severe first relapse (Expanded Disability Status Scale worsening > 1.0 point), and Cox proportional hazards models to evaluate factors associated with time to recovery. Predictors included age, sex, disease duration, baseline Expanded Disability Status Scale, T2 lesion volume, contrast-enhancing lesions, relapse severity, corticosteroid treatment and treatment arm. Results: Across all trials, disease-modifying treatments significantly reduced the annualized relapse rate (p < 0.0001) compared to placebo or interferon as an active comparator, but were not associated with relapse severity or recovery time. Relapse recovery followed a similar two-phase course in all trials, with most recovery occurring within 90–120 days. Treatment arm and corticosteroid use were not significantly associated with the time to recovery in any dataset. Conclusions: While disease-modifying treatments reduce relapse frequency, they did not modify relapse severity or recovery once a relapse occurred. These findings suggest that disease-modifying treatments primarily prevent inflammatory events rather than alter their clinical evolution.

Multiple Sclerosis Journal
Emory University (US), University of Calgary (CA), Haukeland University Hospital (NO), Hospital Universitari Arnau de Vilanova (ES), University of Alabama at Birmingham (US), Universitair Ziekenhuis Brussel (BE), Hospital de Sant Joan Despí Moisès Broggi (ES), Amsterdam University Medical Centers (NL), Rijnstate Hospital (NL), National MS Center Melsbroek (BE), University of Bergen (NO), Université de Montréal (CA), Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
Multiple Sclerosis Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon